Initial Public Offering

Pfenex set for new direction as it uses its expression technology to develop its biosimilar pipeline

Pfenex focuses on biosimilars post IPO

By Dan Stanton

Revenues from protein production will decline as Pfenex shifts attention to its biosimilar pipeline, the newly public company says.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All